Skip to content
DataLookout
Menu

Institute of Hematology & Blood Diseases Hospital, China clinical trial pipeline

Get alerts when Institute of Hematology & Blood Diseases Hospital, China's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

28 trials changed in the last 30 days: 6 stopped, 16 with notable changes, 6 with minor changes only.

  1. Notable: ZBR · Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM Primary completion pushed from Mar 15, 2025 to Nov 15, 2026 Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2 NCT05914662
  2. Stopped: Optimal Timing of Hepatitis B Vaccination After Transplants Withdrawn before enrolling Institute of Hematology & Blood Diseases Hospital, ChinaPhase 3 NCT06888479
  3. Stopped: Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution Trial terminated Institute of Hematology & Blood Diseases Hospital, ChinaNot applicable NCT06208137
  4. Notable: IASO206 · Relapsed/Refractory Multiple Myeloma Enrollment increased: 12 → 18 participants Institute of Hematology & Blood Diseases Hospital, ChinaEarly Phase 1 NCT07322159
  5. Notable: Impact of Closed PBSC Collection With Reduced Gas-Phase Oxygen Exposure on Graft Quality and Early Engraftment in Allo-HSCT Start date pushed from Oct 1, 2026 to Nov 1, 2026 Institute of Hematology & Blood Diseases Hospital, ChinaNot applicable NCT07904234
  6. Minor: 3 trials marked Unknown by the registry's verification sweep Changed Registry verification sweep3 trials
    1. Minor: 2023-D-ES · Anti-CD38 Antibody Treating Evans Syndrome Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2 NCT06014775
    2. Minor: Use of Blinatumomab · NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation Changed Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Not Yet Recruiting Institute of Hematology & Blood Diseases Hospital, ChinaNot applicable NCT06504186
    3. Minor: ITP · TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Institute of Hematology & Blood Diseases Hospital, ChinaNot applicable NCT04890041
  7. Notable: YTS109 Cell Injection · Relapsed/Refractory Autoimmune Hemolytic Anemia Primary completion pushed from Dec 30, 2025 to Jun 30, 2027 Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1 NCT06770504
  8. Notable: DARA-AA-001 · Daratumumab · Refractory Aplastic Anemia Recruitment opened Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1/2 NCT07287228
  9. Minor: Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia Trial completed Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2 NCT06224257
  10. Stopped: KL003 Cell Injection in Severe Sickle Cell Disease Trial status changed: Not Yet Recruiting → Suspended Institute of Hematology & Blood Diseases Hospital, ChinaNot applicable NCT07436767
  11. Notable: IASO206 · Relapsed/Refractory Autoimmune Hemolytic Anemia Primary completion pushed from Dec 31, 2026 to Dec 31, 2027 Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1 NCT07585071
  12. Stopped: hypo-CASH · Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy · Severe Aplastic Anemia Trial terminated Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2 NCT06695741
  13. Stopped: CD7 CAR T Cells (RD13-02) · Relapsed/Refractory Severe Aplastic Anemia Recruitment suspended Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1 NCT06622694
  14. Stopped: Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients Trial terminated Institute of Hematology & Blood Diseases Hospital, ChinaNot applicable NCT06219239
  15. Notable: VRD-based Regimen Combined With CART-ASCT-CART2 Treatment · Primary Plasma Cell Leukemia Primary endpoint(s) modified Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2 NCT05870917
  16. Notable: Growth and Development-related Outcomes · Transfusion-dependent Beta-thalassemia After Gene Therapy Primary completion moved earlier from Dec 31, 2028 to Dec 31, 2027 Institute of Hematology & Blood Diseases Hospital, ChinaNot specified NCT05991336
  17. Notable: CAR T-cell Therapy Targeting CD19 and BCMA · AIHA Who Have Failed ≥3 Lines of Therapy Primary completion pushed from Feb 5, 2026 to Jan 12, 2027 Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1 NCT06733610
  18. Notable: Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia Primary completion pushed from Dec 31, 2026 to Dec 31, 2027 Institute of Hematology & Blood Diseases Hospital, ChinaNot specified NCT06921980
  19. Notable: KL003 Cell Injection · Transfusion-dependent β-thalassemia Primary completion pushed from Aug 20, 2025 to Aug 20, 2027 Institute of Hematology & Blood Diseases Hospital, ChinaNot applicable NCT05860595
  20. Notable: F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia Recruitment opened Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1 NCT07816341
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-17 NCT07943039 Safety and Efficacy of pALG in Conditioning Regimen for HLA-Matched Sibling HSCT in… Not Yet Recruiting
2026-11-13 NCT07936162 Immune Reconstitution and Clinical Prognosis Following Umbilical Cord Blood… Recruiting
2026-11-12 NCT07930793 Aplastic Anemia Life-Course Cohort Study Recruiting
2026-11-12 NCT07932054 Immune Reconstitution Characteristics and Influencing Factors Following Umbilical Cord… Recruiting
2026-11-06 NCT07921550 Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by… Not Yet Recruiting
2026-11-06 NCT07921615 QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center… Phase 2 Not Yet Recruiting
2026-11-05 NCT07919119 Risk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients… Not Yet Recruiting
2026-10-29 NCT07903623 QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia Phase 2 Recruiting
2026-10-29 NCT07903636 QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease Phase 2 Not Yet Recruiting
2026-10-29 NCT07903649 A Randomized, Controlled Clinical Study on the Efficacy and Safety of Umbilical Cord… Phase 2 Completed

Active trials by phase

Early Phase 1
18
Phase 1
34
Phase 1/2
26
Phase 2
104
Phase 2/3
5
Phase 3
11
Phase 4
5
Not charted: 74 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Institute of Hematology & Blood Diseases Hospital, China's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free